Hsuan-Chen Liu, Simone Capuani, Andrew A Badachhape, Nicola Di Trani, Daniel Davila Gonzalez, Robin S Vander Pol, Dixita I Viswanath, Shani Saunders, Nathanael Hernandez, Ketan B Ghaghada, Shu-Hsia Chen, Elizabeth Nance, Ananth V Annapragada, Corrine Ying Xuan Chua, Alessandro Grattoni
Immune checkpoint inhibitors (ICI), pembrolizumab and atezolizumab, were recently approved for treatment-refractory triple-negative breast cancer (TNBC), where those with Programmed death-ligand 1 (PD-L1) positive early-stage disease had improved responses. ICIs are administered systemically in the clinic, however, reaching effective therapeutic dosing is challenging due to severe off-tumor toxicities. As such, intratumoral (IT) injection is increasingly investigated as an alternative delivery approach. However, repeated administration, which sometimes is invasive, is required due to rapid drug clearance from the tumor caused by increased interstitial fluid pressure...
November 2023: Bioengineering & Translational Medicine